



## Seroquel<sup>®</sup>/Seroquel XR<sup>®</sup> (quetiapine) – New warning

- On November 29, 2018, the FDA approved an update to the *Warnings and Precautions* section of the [Seroquel \(quetiapine\)](#) and [Seroquel XR \(quetiapine\)](#) drug labels regarding the risk of anticholinergic (antimuscarinic) effects.
  - Generic versions of Seroquel tablets and Seroquel XR extended-release tablets are available.
- Norquetiapine, an active metabolite of quetiapine, has moderate to strong affinity for several muscarinic receptor subtypes. This contributes to anticholinergic adverse reactions when quetiapine-containing products are used at therapeutic doses, taken concomitantly with other anticholinergic medications, or taken in overdose.
  - Quetiapine should be used with caution in patients receiving medications having anticholinergic (antimuscarinic) effects.
  - Constipation was a commonly reported adverse event in patients treated with quetiapine and represents a risk factor for intestinal obstruction. Intestinal obstruction has been reported with quetiapine, including fatal reports in patients who were receiving multiple concomitant medications that decrease intestinal motility.
  - Quetiapine should be used with caution in patients with a current diagnosis or prior history of urinary retention, clinically significant prostatic hypertrophy, or constipation, or increased intraocular pressure.
- Seroquel and Seroquel XR carry boxed warnings for increased mortality in elderly patients with dementia-related psychosis; and suicidal thoughts and behaviors



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.